Are norepinephrine (NE) and noradrenaline (Norad) the same drug and can they be used interchangeably for treating acute hypotension or septic shock?

Norepinephrine and Noradrenaline Are the Same Drug

Norepinephrine (NE) and noradrenaline (Norad) are identical medications—simply different names for the same compound—and can be used completely interchangeably for treating acute hypotension and septic shock. 1

Nomenclature Clarification

The confusion arises from regional naming conventions:

• Norepinephrine is the International Nonproprietary Name (INN) and the term predominantly used in North America
• Noradrenaline is the British Approved Name (BAN) and commonly used in Europe and other regions
• Both refer to the same catecholamine vasopressor with identical pharmacological properties

The FDA-approved drug label explicitly refers to "Norepinephrine Bitartrate Injection" for raising blood pressure in adult patients with severe, acute hypotension 1, while international guidelines use both terms interchangeably when discussing the same medication.

Clinical Use in Septic Shock

Norepinephrine/noradrenaline is unequivocally the first-choice vasopressor for septic shock (strong recommendation, moderate quality evidence) 2. The Surviving Sepsis Campaign 2016 guidelines establish this as the gold standard across all participating international societies.

Key Clinical Algorithm:

Initial Management:

• Target mean arterial pressure (MAP) of 65 mmHg initially 2
• Start norepinephrine as first-line vasopressor (grade 1B recommendation) 2
• Place arterial catheter as soon as practical if resources available 2

Second-Line Options (if MAP target not achieved):

• Add vasopressin (up to 0.03 U/min) to raise MAP or decrease norepinephrine dosage 2
• Add epinephrine as alternative second-line agent 2

Agents to Avoid:

• Dopamine should only be used in highly selected patients with low risk of tachyarrhythmias and absolute/relative bradycardia (grade 2C) 2
• Phenylephrine reserved only for specific circumstances: serious arrhythmias with norepinephrine, known high cardiac output with persistent low BP, or salvage therapy (grade 1C) 2

Evidence Base

The global perspective on vasoactive agents demonstrates that no randomised trial shows survival advantage when comparing norepinephrine to other vasopressors 3. However, norepinephrine is recommended based on superior safety profile and fewer organ dysfunction effects:

• The SOAP II trial showed dopamine increased arrhythmic events compared to norepinephrine, though no overall mortality difference 3
• Mortality rates increased during a 6-month norepinephrine shortage in 26 US hospitals when replaced primarily with phenylephrine and dopamine 3
• Drugs with positive chronotropic effects (dopamine, levosimendan, epinephrine) may be associated with higher risk of death 3

Critical Pitfalls to Avoid

Do not confuse the names: Any prescription, order, or protocol using "noradrenaline" refers to the exact same medication as "norepinephrine." There is no need to verify equivalency or adjust dosing—they are pharmaceutically identical.

Regional variations: When reviewing international literature or guidelines, recognize that European sources typically use "noradrenaline" while North American sources use "norepinephrine," but the clinical recommendations apply equally to both terms.

Drug shortages: Be aware that during norepinephrine shortages, substitution with alternative vasopressors (particularly phenylephrine and dopamine) has been associated with increased mortality 3, reinforcing its status as the optimal first-line agent.